IDEAYA Biosciences’ (IDYA) “Overweight” Rating Reiterated at Stephens

IDEAYA Biosciences (NASDAQ:IDYA)‘s stock had its “overweight” rating reissued by investment analysts at Stephens in a note issued to investors on Friday,Benzinga reports. They currently have a $50.00 price objective on the stock. Stephens’ price target points to a potential upside of 136.13% from the company’s current price.

IDYA has been the subject of a number of other reports. Oppenheimer reaffirmed an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. UBS Group assumed coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.58.

IDEAYA Biosciences Stock Up 2.0 %

NASDAQ IDYA traded up $0.42 during trading hours on Friday, hitting $21.18. 445,900 shares of the stock were exchanged, compared to its average volume of 847,317. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -9.04 and a beta of 0.82. IDEAYA Biosciences has a 12-month low of $20.63 and a 12-month high of $47.74. The stock has a 50-day moving average of $24.49 and a 200 day moving average of $30.11.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.86). On average, equities research analysts expect that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

Institutional Trading of IDEAYA Biosciences

Several institutional investors have recently made changes to their positions in the stock. KBC Group NV boosted its holdings in IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after acquiring an additional 513 shares during the last quarter. Amalgamated Bank increased its position in IDEAYA Biosciences by 22.9% during the 3rd quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock worth $90,000 after purchasing an additional 530 shares in the last quarter. Rhumbline Advisers lifted its position in IDEAYA Biosciences by 0.5% during the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after buying an additional 585 shares in the last quarter. US Bancorp DE raised its stake in shares of IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after acquiring an additional 689 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in IDEAYA Biosciences by 35.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after purchasing an additional 796 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.